MCID: OCL006
MIFTS: 53

Ocular Hypertension

Categories: Eye diseases, Neuronal diseases

Aliases & Classifications for Ocular Hypertension

MalaCards integrated aliases for Ocular Hypertension:

Name: Ocular Hypertension 12 54 43 15 17 71
Hypertension, Ocular 39

Classifications:



External Ids:

Disease Ontology 12 DOID:9282
ICD9CM 34 365.04
MeSH 43 D009798
NCIt 49 C3285
SNOMED-CT 67 4210003
ICD10 32 H40.05
UMLS 71 C0028840

Summaries for Ocular Hypertension

Disease Ontology : 12 An eye disease that is characterized by elevated intraocular pressure in the absence of optic nerve damage or visual field loss.

MalaCards based summary : Ocular Hypertension, also known as hypertension, ocular, is related to glaucoma, primary open angle and open-angle glaucoma, and has symptoms including eye manifestations An important gene associated with Ocular Hypertension is MYOC (Myocilin), and among its related pathways/superpathways are p70S6K Signaling and NFAT and Cardiac Hypertrophy. The drugs Ketorolac and Dipivefrin have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and endothelial, and related phenotypes are homeostasis/metabolism and cellular

Wikipedia : 74 Ocular hypertension is the presence of elevated fluid pressure inside the eye (intraocular pressure),... more...

Related Diseases for Ocular Hypertension

Diseases related to Ocular Hypertension via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 212)
# Related Disease Score Top Affiliating Genes
1 glaucoma, primary open angle 31.9 TMCO1 TGFB2 RHO PTGFR OPTN MYOC
2 open-angle glaucoma 31.3 TMCO1 TGFB2 PTGFR OPTN MYOC CRYAA
3 intraocular pressure quantitative trait locus 31.1 TMCO1 TGFB2 PTGFR OPTN MYOC CRYAA
4 optic nerve disease 30.7 OPTN MYOC JUN CRYAA
5 microvascular complications of diabetes 5 30.4 TGFB2 RHO CRYAA AKT1
6 glaucoma, normal tension 30.4 TMCO1 OPTN MYOC CRYAA
7 glaucoma-related pigment dispersion syndrome 30.3 TMCO1 OPTN MYOC
8 macular holes 30.1 TGFB2 RLBP1 CRYAA
9 steroid-induced glaucoma 30.0 TGFB2 OPTN NR3C1 MYOC CRYAA
10 retinal vascular disease 30.0 RHO CRYAA AKT1
11 macular degeneration, age-related, 1 30.0 TGFB2 RLBP1 RHO MYOC CRYAA AKT1
12 retinal degeneration 29.8 RLBP1 RHO OPTN EPO CRYAA
13 chronic closed-angle glaucoma 29.8 TGFB2 MYOC
14 retinal disease 29.7 RLBP1 RHO OPTN MYOC CRYAA
15 glaucoma 1, open angle, a 29.7 OPTN MYOC
16 juvenile glaucoma 29.6 OPTN MYOC CRYAA
17 hypertension, essential 29.4 RHOA NR3C1 MTOR JUN HSD11B1 FOS
18 eye disease 29.4 TGFB2 RLBP1 RHO OPTN MYOC JUN
19 exudative vitreoretinopathy 1 29.4 RHO MYOC MTOR EPO CRYAA
20 retinitis pigmentosa 28.4 RLBP1 RHOA RHO MYOC MTOR JUN
21 glaucoma 3, primary congenital, a 11.1
22 glaucoma 3, primary infantile, b 11.1
23 hydrophthalmos 11.1
24 yemenite deaf-blind hypopigmentation syndrome 10.5
25 uveitis 10.5
26 cataract 10.5
27 peripheral retinal degeneration 10.4 RLBP1 RHO MYOC
28 solar retinopathy 10.4 RLBP1 RHO
29 macular retinal edema 10.3
30 optic nerve hypoplasia, bilateral 10.3 TMCO1 RLBP1 RHO MYOC
31 joint laxity, short stature, and myopia 10.3
32 myopia 10.3
33 exfoliation syndrome 10.3
34 amelogenesis imperfecta, type ig 10.3 JUN FOS AKT1
35 retinal detachment 10.3
36 retinal vein occlusion 10.3
37 conjunctivitis 10.3
38 ocular hyperemia 10.2
39 in situ carcinoma 10.2 NR3C1 FKBP4 AKT1
40 iridocyclitis 10.2
41 refractive error 10.2
42 keratitis, hereditary 10.2
43 primary angle-closure glaucoma 10.2
44 cystic kidney disease 10.2 MTOR JUN EPO AKT1
45 autoimmune uveitis 10.2 TGFB2 RLBP1 CRYAA
46 retinal ischemia 10.1
47 neuropathy 10.1
48 diabetic macular edema 10.1
49 vitreous disease 10.1 TGFB2 RLBP1 RHO CRYAA
50 allergic conjunctivitis 10.1

Comorbidity relations with Ocular Hypertension via Phenotypic Disease Network (PDN):


Glaucoma, Primary Open Angle

Graphical network of the top 20 diseases related to Ocular Hypertension:



Diseases related to Ocular Hypertension

Symptoms & Phenotypes for Ocular Hypertension

UMLS symptoms related to Ocular Hypertension:


eye manifestations

MGI Mouse Phenotypes related to Ocular Hypertension:

45 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.34 AKT1 CA2 EPO FKBP4 FKBP5 FOS
2 cellular MP:0005384 10.3 AKT1 EPO FKBP4 FOS HSD11B1 JUN
3 growth/size/body region MP:0005378 10.29 AKT1 CA2 FKBP4 FOS HSD11B1 JUN
4 immune system MP:0005387 10.25 AKT1 CA2 EPO FOS HSD11B1 JUN
5 endocrine/exocrine gland MP:0005379 10.24 AKT1 CA2 FKBP4 FOS HSD11B1 JUN
6 mortality/aging MP:0010768 10.21 AKT1 CA2 EPO FKBP4 FKBP5 FOS
7 hematopoietic system MP:0005397 10.2 AKT1 EPO FOS HSD11B1 JUN MTOR
8 embryo MP:0005380 10.16 AKT1 EPO FKBP4 FOS JUN MTOR
9 nervous system MP:0003631 10.1 AKT1 CA2 FOS HSD11B1 JUN MTOR
10 normal MP:0002873 9.96 AKT1 EPO FKBP5 FOS JUN MTOR
11 renal/urinary system MP:0005367 9.76 CA2 FKBP4 FKBP5 MTOR NR3C1 RHOA
12 respiratory system MP:0005388 9.56 AKT1 CA2 EPO HSD11B1 JUN MTOR
13 skeleton MP:0005390 9.32 AKT1 CA2 EPO FOS JUN MTOR

Drugs & Therapeutics for Ocular Hypertension

Drugs for Ocular Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 148)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
2
Dipivefrin Approved Phase 4 52365-63-6 3105
3
Carteolol Approved Phase 4 51781-06-7 2583
4
Sorbitol Approved Phase 4 50-70-4 5780
5
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294 5496
6
Loteprednol Approved, Experimental Phase 4 129260-79-3, 82034-46-6 9865442 444025
7
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
8
Clonidine Approved Phase 4 4205-90-7 2803
9
Fluorouracil Approved Phase 4 51-21-8 3385
10
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
11
tannic acid Approved Phase 4 1401-55-4
12
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
13
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
14
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
15
Cefuroxime Approved Phase 4 55268-75-2 5479529 5361202
16
Brinzolamide Approved Phase 4 138890-62-7 68844
17
Dorzolamide Approved Phase 4 120279-96-1 5284549 3154
18 Cloprostenol Vet_approved Phase 4 54276-21-0
19 Ketorolac Tromethamine Phase 4
20 Contraceptive Agents Phase 4
21 Sympatholytics Phase 4
22 Anti-Infective Agents, Local Phase 4
23 Benzalkonium Compounds Phase 4
24 Anti-Allergic Agents Phase 4
25 Analgesics Phase 4
26 Vitamins Phase 4
27 Respiratory System Agents Phase 4
28 Anti-Asthmatic Agents Phase 4
29 Dermatologic Agents Phase 4
30 Bronchodilator Agents Phase 4
31 Mitomycins Phase 4
32 Immunosuppressive Agents Phase 4
33 Excitatory Amino Acid Antagonists Phase 4
34 Anesthetics, General Phase 4
35 Anesthetics, Intravenous Phase 4
36 Anesthetics, Dissociative Phase 4
37 Anesthetics Phase 4
38 cefuroxime axetil Phase 4
39 Adrenergic alpha-Agonists Phase 4
40 Adrenergic Agonists Phase 4
41 Brimonidine Tartrate Phase 4 70359-46-5
42 Pharmaceutical Solutions Phase 4
43 Carbonic Anhydrase Inhibitors Phase 4
44 Adrenocorticotropic Hormone Phase 4
45 Melanocyte-Stimulating Hormones Phase 4
46 beta-Endorphin Phase 4
47
Adenosine Approved, Investigational Phase 3 58-61-7 60961
48
Triamcinolone Approved, Vet_approved Phase 2, Phase 3 124-94-7 31307
49
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
50
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9 24083

Interventional clinical trials:

(show top 50) (show all 607)
# Name Status NCT ID Phase Drugs
1 A Prospective, Randomized Evaluation of Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost Ophthalmic Solution 0.004% Unknown status NCT01444040 Phase 4 Travoprost
2 IntraVitreal Triamcinolone Acetonide: Preventing Raised Eye-pressure by Tracking Elevations After Topical Steroids Unknown status NCT00744666 Phase 4 Prednisolone 1% topical eye drops
3 An Open Label,Switch Study of the Safety and Efficacy of Combigan Ophthalmic Solution(Brimonidine 0.2% and Timolol 0.5%)With Latanoprost Compared With Latanoprost Monotherapy in Patient With Glaucoma or Ocular Hypertension. Unknown status NCT00442312 Phase 4 Combigan Ophthalmic Solutiom
4 IOP and Tolerability Study of Preserved Bimatoprost 0.1% or Tafluprost Unit Dose Preservative Free 15microgram/ml, in Patients With OHT or Glaucoma Suitable for Prostaglandin Therapy Unknown status NCT02471105 Phase 4 Preserved Bimatoprost 0.01%;Tafluprost Unit Dose Preservative Free 15microgram/ml
5 A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treated With One Suprachoroidal Stent Unknown status NCT01252914 Phase 4
6 Efficiency of XAL-EASE Device in Glaucoma and/or Ocular Hypertension (OHT) Patients, Treated With Xalatan or Xalacom Unknown status NCT01125306 Phase 4
7 Randomized Crossover Trial Comparing the Hypotensive Effect of Generic Travoprost With That of the Brand Name Travoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Unknown status NCT02796560 Phase 4 Brand name travoprost;Generic travoprost
8 A Prospective, Randomized, Controlled Study to Assess Efficacy,Safety, and Tolerability of Selective Laser Trabeculoplasty vs. Pattern Laser Trabeculoplasty in Patients With Open-angle Glaucoma Unknown status NCT02231515 Phase 4
9 An 8 Week Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Open Angle Glaucoma Unknown status NCT02792803 Phase 4 Xalatan;Apo-Latanoprost;Co-Latanoprost
10 A Randomised Controlled Trial to Compare the Clinical Effectiveness of Selective Laser Trabeculoplasty (SLT) Versus Topical Therapy in the Treatment of Pseudoexfoliative Glaucoma Unknown status NCT01704989 Phase 4 Prostagladin
11 A Multiple-Dose Study of the IOP-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% When Added to a PGA as Adjunctive Therapy Over a 24 Hour Period in Patients With Glaucoma or Ocular Hypertension Completed NCT00300079 Phase 4 brinzolamide 1.0%
12 Examination of Ocular Surface Effects With Administration of TRAVATAN Z® and Xalatan® Completed NCT00708422 Phase 4 Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®);Latanoprost ophthalmic solution 0.005% (XALATAN®)
13 A Double-Masked, Placebo-Controlled, Paired Comparison Study of the Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension Completed NCT00061503 Phase 4 Travoprost
14 A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension Completed NCT02020512 Phase 4 0.03% Bimatoprost
15 A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular Hypertension Completed NCT02003534 Phase 4 0.15% Brimonidine Tartrate
16 Safety and Efficacy of Brinzolamide Dosed TID With Dorzolamide Dosed TID in Reducing Intraocular Pressure in Patients With Open Angle Glaucoma or Ocular Hypertension Completed NCT00761995 Phase 4 Azopt;Cosopt
17 A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension Completed NCT02061683 Phase 4 Bimatoprost 0.03%
18 Comparison of Bimatoprost 0.03% Monotherapy vs. Dual Therapy With Travoprost 0.004% and Timolol 0.5% in Patients With Glaucoma and Ocular Hypertension Completed NCT00348023 Phase 4 Bimatoprost 0.03%, Travoprost 0.004%, Timolol 0.5%
19 A Randomized Post-Marketing Efficacy And Safety Study Of Xalatan Compared With "Usual Care" Over 36 Months In Patients With Primary Open-Angle Glaucoma, Exfoliative Glaucoma Or Ocular Hypertension Completed NCT00140062 Phase 4 latanoprost 0.005% (Xalatan)
20 A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH) Completed NCT01594970 Phase 4 Bimatoprost 0.01%
21 Safety and Efficacy of Using the Travoprost/Timolol Fixed Combination (DuoTrav®) in Patients With Open-Angle Glaucoma or Uncontrolled Ocular Hypertension by Beta-blocker Monotherapy (Timolol 0.5%) Completed NCT01336569 Phase 4 Travoprost 0.004%/timolol maleate 0.5% fixed combination
22 A Multicenter, Open-Label Study To Evaluate The Tolerability Of Preservative Free Dorzolamide-Timolol Therapy In Patients Untreated With Open-Angle Glaucoma Or Ocular Hypertension And Dry Eye(s) Completed NCT00545064 Phase 4 dorzolamide hydrochloride (+) timolol maleate
23 Assessment of Late Day IOP Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®) Completed NCT01464424 Phase 4 Travoprost 0.004% ophthalmic solution;Bimatoprost 0.01% ophthalmic solution
24 DuoTrav® Eye Drops As Replacement Therapy Program Completed NCT00828906 Phase 4 DuoTrav
25 Assessing Cosopt Switch Patients Completed NCT00273442 Phase 4 timolol maleate;dorzolamide/timolol maleate fixed combination
26 24-hour IOP-lowering Effect of Brimonidine 0.1% Completed NCT00457795 Phase 4 brimonidine 0.1% (Alphagan® P)
27 Examination of Ocular Surface Effects With Administration of TRAVATAN Z® and XALATAN® Completed NCT00798759 Phase 4 Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®);Latanoprost ophthalmic solution 0.005% (XALATAN®)
28 A Single Dose Comfort Comparison of Travatan Z in One Eye Versus Xalatan in the Opposite Eye in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Completed NCT00527592 Phase 4 Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®);Latanoprost ophthalmic solution 0.005% (XALATAN®)
29 A Prospective, Randomized Evaluation of Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent) or Travoprost Ophthalmic Solution 0.004% Completed NCT01443988 Phase 4 Travoprost
30 Pilot Study Comparison of Combigan Two Times Daily (BID) vs Simbrinza Three Times Daily (TID) in Subjects Currently Treated With Latanoprost For Open-Angle Glaucoma or Ocular Hypertension Completed NCT02167035 Phase 4 Combigan Two Times Daily (BID);Simbrinza Three Times Daily (TID)
31 Evaluation of the Safety of GANFORT® (Bimatoprost 0.03% Plus Timolol 0.5%) Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension Completed NCT02571712 Phase 4 bimatoprost 0.03% plus timolol 0.5%
32 Prospective, Randomized, Multi-Center Study to Evaluate the Efficacy and Tolerability of DuoTrav® in Patients Previously Uncontrolled on a Beta-blocker Completed NCT02003391 Phase 4 Beta-blocker monotherapy;Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution
33 An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects Completed NCT00811564 Phase 4 fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution;latanoprost 0.005%
34 24-Hour Intraocular Pressure (IOP) And Blood Pressure Control In Glaucoma And Ocular Hypertension Patients Completed NCT00330577 Phase 4 timolol maleate 0.5%;latanoprost/timolol fixed combination;placebo (artificial tears)
35 A 2-year, Multicenter, Double-masked, Randomized, Parallel Study of the Safety of LUMIGAN® 0.1 mg/mL Compared With LUMIGAN® 0.3 mg/mL in Patients With Glaucoma or Ocular Hypertension Completed NCT01298700 Phase 4 bimatoprost 0.01% ophthalmic solution;bimatoprost 0.03% ophthalmic solution
36 Assessing the Efficacy and Tolerability of Changing to DUOTRAV® (Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination), as Replacement Therapy in Patients Previously on Bimatoprost 0.03%/Timolol 0.5% Therapy (Fixed or Unfixed) Completed NCT01327599 Phase 4 Travoprost 0.004%+Timolol 0.5% ophthalmic solution
37 Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects Completed NCT00735449 Phase 4 Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%;timolol maleate 0.5%;latanoprost 0.005%
38 Assessing the Efficacy and Tolerability of TRAVATAN® Solution Without BAK, Containing Polyquad® Preservative (Travoprost 0.004%) Versus LUMIGAN® 0.01% Solution With BAK (Bimatoprost 0.01%) in Treatment Naïve Patients With Ocular Hypertension or Open Angle Glaucoma Completed NCT01664039 Phase 4 Travoprost 0.004% ophthalmic solution;Bimatoprost 0.01% ophthalmic solution
39 Open Multicenter Study on the Efficacy of Xalatan at 3 Months as First-Line Therapy in Naive Patients With Ocular Hypertension (OH) or Open Angle Glaucoma (OAG), Based on Initial Intraocular Pressure (IOP): 20 mmHg Less Than or Equal to IOP Less Than 24 mmHg, IOP Greater Than or Equal to 24 mmHg Completed NCT00647101 Phase 4 Latanoprost
40 Multi-Center Study Comparing Efficacy and Tolerability of TRAVATAN® BAK-free (0.004% Travoprost) in Patients Previously on Latanoprost Ophthalmic Solution 0.005% Monotherapy Completed NCT01510145 Phase 4 Travoprost 0.004% BAK-free
41 Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Canada Completed NCT01415401 Phase 4 Brinzolamide 1% / timolol 0.5% maleate fixed combination
42 Prospective, Randomized, Single-Center Study to Evaluate 24-hour Intraocular Pressure Control With Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination Therapy Completed NCT01978600 Phase 4 Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension;Timolol Maleate 0.5%
43 A Twelve-Week, Double Masked, Parallel Group, Study of Travoprost 0.004% Compared to Timolol 0.5% in Patients With Open-Angle Glaucoma or Ocular Hypertension Completed NCT00763061 Phase 4 Travoprost 0.004% Ophthalmic Solution (Travatan);Timolol 0.5% Ophthalmic Solution (Timoptic)
44 Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension Completed NCT00759239 Phase 4 Travoprost 0.004% / Timolol maleate 0.5%;Travoprost 0.004% / Timolol maleate 0.5%
45 Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With Glaucoma or Ocular Hypertension Completed NCT00541242 Phase 4 bimatoprost 0.03% eye drops;latanoprost 0.005% eye drops
46 Latanoprost Versus Fotil Completed NCT00304785 Phase 4 latanoprost 0.005%;Fotil;placebo
47 Efficacy Of The Bimatoprost/Timolol Fixed Combination In Patients Treated With Bimatoprost for Primary Open Angle Glaucoma, Exfoliation Glaucoma or Ocular Hypertension. Completed NCT00941096 Phase 4 Bimatoprost and Bimatoprost/Timolol fixed combination.
48 Patient Preference Comparison of AZARGA Versus COSOPT After Single Doses in Patients With Open-Angled Glaucoma or Ocular Hypertension Completed NCT01471158 Phase 4 Brinzolamide/Timolol Maleate Fixed Combination (AZARGA);Dorzolamide/timolol Maleate Fixed Combination (COSOPT)
49 The Efficacy and Safety of Brinzolamide 1%/Timolol 0.5% Fixed Combination Versus Dorzolamide 1%/Timolol 0.5% in Patients With Open-Angle Glaucoma and Ocular Hypertension Completed NCT02325518 Phase 4 Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension;Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution;Subject's habitual PGA monotherapy
50 Investigation of the Effect of Travoprost Ophthalmic Solution of Lowering Intraocular Pressure in Patients With Normal Tension Glaucoma Completed NCT01995136 Phase 4 Travoprost Ophthalmic Solution 0.004%

Search NIH Clinical Center for Ocular Hypertension

Inferred drug relations via UMLS 71 / NDF-RT 50 :


apraclonidine
Apraclonidine hydrochloride
Mannitol
Mannitol hexanitrate
MANNITOL PWDR
Urea
UREA POWDER

Cochrane evidence based reviews: ocular hypertension

Genetic Tests for Ocular Hypertension

Anatomical Context for Ocular Hypertension

MalaCards organs/tissues related to Ocular Hypertension:

40
Eye, Testes, Endothelial, Retina, Thyroid, Bone, Bone Marrow

Publications for Ocular Hypertension

Articles related to Ocular Hypertension:

(show top 50) (show all 5038)
# Title Authors PMID Year
1
Assessment of SNPs associated with the human glucocorticoid receptor in primary open-angle glaucoma and steroid responders. 61 54
20376328 2010
2
Overexpression of myocilin in the Drosophila eye activates the unfolded protein response: implications for glaucoma. 61 54
19148291 2009
3
[Expression of glucocorticoid receptors alpha and beta in mononuclear cells of peripheral blood in patients with glucocorticoid-induced ocular hypertension]. 54 61
19484926 2009
4
Aqueous humor myocilin protein levels in normal, genetic carriers, and glaucoma Beagles. 54 61
18435660 2008
5
Role of MYOC and OPTN sequence variations in Spanish patients with primary open-angle glaucoma. 61 54
17615537 2007
6
The variant N363S of glucocorticoid receptor in steroid-induced ocular hypertension in Hungarian patients treated with photorefractive keratectomy. 54 61
17563720 2007
7
Myocilin-associated exosomes in human ocular samples. 61 54
17094967 2007
8
Coiled-coil targeting of myocilin to intracellular membranes. 54 61
16973161 2006
9
Novel myocilin mutation in a Chinese family with juvenile-onset open-angle glaucoma. 61 54
16401791 2006
10
Characterization of rabbit myocilin: Implications for human myocilin glycosylation and signal peptide usage. 54 61
12697062 2003
11
Myocilin glaucoma. 54 61
12504739 2002
12
Rapid mutation detection by the transgenomic wave analyser DHPLC identifies MYOC mutations in patients with ocular hypertension and/or open angle glaucoma. 61 54
11815346 2002
13
Glucocorticoid induction of the glaucoma gene MYOC in human and monkey trabecular meshwork cells and tissues. 54 61
11431441 2001
14
Evaluation of the myocilin (MYOC) glaucoma gene in monkey and human steroid-induced ocular hypertension. 54 61
11133859 2001
15
Characterization and differential expression of a human gene family of olfactomedin-related proteins. 54 61
11006633 2000
16
Pathophysiology and management of glaucoma and ocular hypertension related to trauma. 61
32057763 2020
17
Comparing silicone oil-induced ocular hypertension with other inducible glaucoma models in mice. 61
32209765 2020
18
MCT2 overexpression rescues metabolic vulnerability and protects retinal ganglion cells in two models of glaucoma. 61
32422282 2020
19
Current management of uveitis-associated ocular hypertension and glaucoma. 61
31816329 2020
20
Correlation Between Office-Hour and Peak Nocturnal Intraocular Pressure in Patients Treated with Prostaglandin Analogs. 61
32087142 2020
21
Protective effects of carnosic acid on retinal ganglion cells in acute ocular hypertension rats. 61
32277323 2020
22
Comparison of a commercial spectral-domain OCT and swept-source OCT based on an angiography scan for measuring circumpapillary retinal nerve fibre layer thickness. 61
31585965 2020
23
Omidenepag Isopropyl Versus Latanoprost in Primary Open-angle Glaucoma and Ocular Hypertension: ThePhase 3 AYAME Study. 61
32533949 2020
24
The impact of intraocular pressure fluctuations and other factors on conversion of ocular hypertension to primary open-angle glaucoma. 61
32065355 2020
25
Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study. 61
32572719 2020
26
Evaluation of a Primary Open-Angle Glaucoma Prediction Model Using Long-term Intraocular Pressure Variability Data: A Secondary Analysis of 2 Randomized Clinical Trials. 61
32496526 2020
27
Fibronectin extra domain A (FN-EDA) elevates intraocular pressure through Toll-like receptor 4 signaling. 61
32555351 2020
28
Ocular Perfusion Pressure and the Risk of Open-Angle Glaucoma: Systematic Review and Meta-analysis. 61
32572072 2020
29
Medical management of pediatric glaucoma: lessons learned from randomized clinical trials. 61
32483675 2020
30
Molecular taxonomy of human ocular outflow tissues defined by single-cell transcriptomics. 61
32439707 2020
31
Group II metabotropic glutamate receptor agonist promotes retinal ganglion cell survival by reducing neuronal excitotoxicity in a rat chronic ocular hypertension model. 61
32101763 2020
32
Biallelic CPAMD8 Variants Are a Frequent Cause of Childhood and Juvenile Open-Angle Glaucoma. 61
32085876 2020
33
A novel intraocular lens designed for sutureless scleral fixation: surgical series. 61
32529278 2020
34
Dose-response and normal tissue complication probabilities after proton therapy for choroidal melanomas. 61
32574763 2020
35
Intraocular pressure elevation associated with blood in Schlemm's canal after strabismus surgery. 61
32195447 2020
36
Bimatoprost Implant: First Approval. 61
32447639 2020
37
Analysis of Plasma Hydrogen Sulfide, Homocysteine, and L-Cysteine in Open-Angle Glaucoma Patients. 61
32493106 2020
38
Contributing ocular comorbidity to end-of-life visual acuity in medically treated glaucoma patients, ocular hypertension and glaucoma suspect patients. 61
32494040 2020
39
Correction to: Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: The VISIONARY Study. 61
32567020 2020
40
Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1). 61
32544560 2020
41
Uveitis and cystoid macular oedema secondary to topical prostaglandin analogue use in ocular hypertension and open angle glaucoma. 61
32532763 2020
42
ICare Pro: Age Dependent Effect of Central Corneal Thickness on Intraocular Pressure in Glaucoma and Ocular Hypertension Patients. 61
31905299 2020
43
Optic nerve head diurnal vessel density variations in glaucoma and ocular hypertension measured by optical coherence tomography angiography. 61
32221692 2020
44
Evaluation of the short- and long-term complications and outcomes of phacoemulsification surgery in alpacas. 61
32510743 2020
45
scAAV2-Mediated C3 Transferase Gene Therapy in a Rat Model with Retinal Ischemia/Reperfusion Injuries. 61
32382585 2020
46
Anterior uveitis secondary to intraocular fiber from a hair enhancement product. 61
32258823 2020
47
Intraocular pressure (IOP) after intravitreal dexamethasone implant (Ozurdex) amongst different geographic populations-GEODEX-IOP study. 61
31570814 2020
48
Real-World Outcomes of Selective Laser Trabeculoplasty in the United Kingdom. 61
31952882 2020
49
Diurnal Measurements of Macular Thickness and Vessel Density on OCT Angiography in Healthy Eyes and Those with Ocular Hypertension and Glaucoma. 61
32555061 2020
50
Glaucomatous Maculopathy: Thickness Differences on Inner and Outer Macular Layers between Ocular Hypertension and Early Primary Open-Angle Glaucoma Using 8 × 8 Posterior Pole Algorithm of SD-OCT. 61
32429480 2020

Variations for Ocular Hypertension

Expression for Ocular Hypertension

Search GEO for disease gene expression data for Ocular Hypertension.

Pathways for Ocular Hypertension

Pathways related to Ocular Hypertension according to GeneCards Suite gene sharing:

(show top 50) (show all 78)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.08 TGFB2 RHOA MTOR JUN FOS AKT1
2
Show member pathways
12.89 TGFB2 RHOA MTOR JUN AKT1
3
Show member pathways
12.86 TGFB2 RHOA MTOR JUN FOS AKT1
4
Show member pathways
12.83 MTOR JUN FOS EPO AKT1
5
Show member pathways
12.8 TGFB2 MTOR JUN FOS AKT1
6
Show member pathways
12.74 RHOA MTOR JUN FOS AKT1
7 12.7 TGFB2 RHOA MTOR JUN FOS EPO
8
Show member pathways
12.63 TGFB2 MTOR JUN FOS AKT1
9
Show member pathways
12.61 RHOA MTOR JUN FOS AKT1
10
Show member pathways
12.61 MTOR JUN FOS FKBP5 FKBP4 AKT1
11
Show member pathways
12.49 RHOA MTOR JUN FOS AKT1
12
Show member pathways
12.47 MTOR JUN FOS AKT1
13
Show member pathways
12.45 MTOR JUN FOS AKT1
14 12.45 RHOA JUN FOS AKT1
15
Show member pathways
12.43 RHOA JUN FOS AKT1
16 12.43 RHOA MTOR JUN AKT1
17
Show member pathways
12.43 TGFB2 RHOA MTOR JUN FOS
18 12.37 TGFB2 JUN FOS AKT1
19
Show member pathways
12.37 MTOR JUN FOS AKT1
20 12.36 RHOA JUN FOS AKT1
21 12.34 RHOA JUN FOS AKT1
22 12.33 TGFB2 RHOA MTOR AKT1
23
Show member pathways
12.33 RHOA JUN FOS AKT1
24
Show member pathways
12.32 MTOR JUN FOS AKT1
25
Show member pathways
12.3 RHOA NR3C1 MTOR JUN FOS AKT1
26
Show member pathways
12.28 TGFB2 JUN FOS AKT1
27
Show member pathways
12.24 TGFB2 NR3C1 JUN FOS
28
Show member pathways
12.23 RHOA JUN FOS AKT1
29 12.21 MTOR JUN FOS AKT1
30
Show member pathways
12.19 JUN FOS EPO AKT1
31 12.15 RHO MTOR JUN AKT1
32
Show member pathways
12.14 RHOA JUN FOS AKT1
33 12.11 MTOR JUN FOS AKT1
34
Show member pathways
12.09 MTOR JUN FOS AKT1
35 12.09 RHOA JUN FOS AKT1
36
Show member pathways
12.07 RHOA JUN FOS AKT1
37 12.06 RHOA JUN FOS AKT1
38 12.04 TGFB2 JUN FOS AKT1
39
Show member pathways
12.02 RHOA PTGFR MTOR JUN FOS AKT1
40
Show member pathways
12 RHOA MTOR JUN FOS
41 11.99 RHOA JUN FOS AKT1
42
Show member pathways
11.95 RHOA JUN FOS AKT1
43 11.89 TGFB2 JUN FOS
44 11.89 RHOA FOS AKT1
45 11.89 MTOR JUN FOS AKT1
46
Show member pathways
11.85 JUN FOS AKT1
47 11.81 RHOA JUN FKBP4 AKT1
48 11.79 RHOA JUN FOS
49 11.73 RHOA JUN AKT1
50 11.72 RHOA JUN AKT1

GO Terms for Ocular Hypertension

Cellular components related to Ocular Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 10 TMCO1 SRSF3 RLBP1 RHOA PTGFR OPTN
2 nucleoplasm GO:0005654 9.7 SRSF3 RLBP1 OPTN NR3C1 MTOR JUN
3 transcription factor AP-1 complex GO:0035976 8.62 JUN FOS

Biological processes related to Ocular Hypertension according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 10 TGFB2 PTGFR JUN EPO AKT1
2 negative regulation of apoptotic process GO:0043066 9.98 PTGFR JUN EPO CRYAA AKT1
3 response to organic substance GO:0010033 9.77 JUN CA2 AKT1
4 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.75 TGFB2 MYOC EPO
5 positive regulation of cell growth GO:0030307 9.73 TGFB2 RHOA AKT1
6 aging GO:0007568 9.73 JUN FOS EPO AKT1
7 positive regulation of endothelial cell proliferation GO:0001938 9.71 MTOR JUN AKT1
8 response to mechanical stimulus GO:0009612 9.7 RHOA JUN FOS
9 SMAD protein signal transduction GO:0060395 9.69 TGFB2 JUN FOS
10 positive regulation of smooth muscle cell proliferation GO:0048661 9.67 MTOR JUN AKT1
11 response to lipopolysaccharide GO:0032496 9.67 PTGFR JUN FOS EPO
12 positive regulation of neuron apoptotic process GO:0043525 9.63 TGFB2 RHOA JUN
13 positive regulation of stress fiber assembly GO:0051496 9.58 RHOA MYOC MTOR
14 regulation of glycogen biosynthetic process GO:0005979 9.57 MTOR AKT1
15 anoikis GO:0043276 9.55 MTOR AKT1
16 cellular response to reactive oxygen species GO:0034614 9.5 JUN FOS AKT1
17 heart valve morphogenesis GO:0003179 9.48 TGFB2 MTOR
18 transforming growth factor beta receptor signaling pathway GO:0007179 9.46 TGFB2 RHOA JUN FOS
19 cellular response to cadmium ion GO:0071276 9.43 JUN FOS AKT1
20 negative regulation of cell size GO:0045792 9.13 RHOA MTOR AKT1
21 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 8.92 TGFB2 NR3C1 JUN FOS

Molecular functions related to Ocular Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 FK506 binding GO:0005528 8.96 FKBP5 FKBP4
2 11-cis retinal binding GO:0005502 8.62 RLBP1 RHO

Sources for Ocular Hypertension

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....